Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease
Identifieur interne : 002495 ( Main/Exploration ); précédent : 002494; suivant : 002496Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease
Auteurs : Grégory Porras [France] ; Erwan Bezard [France]Source :
- Experimental neurology : (Print) [ 0014-4886 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Apoptosis, Asymptomatic, Basal ganglion, Clinical Trials as Topic, Dopamine, Dopamine Agents (therapeutic use), Gene therapy, Genetic Therapy (trends), Growth factor, Humans, Nervous system diseases, Neuroprotective Agents (therapeutic use), Parkinson Disease (therapy), Parkinson disease, Subthalamic nucleus.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Neuroprotective Agents.
- therapy : Parkinson Disease.
- trends : Genetic Therapy.
- Animals, Clinical Trials as Topic, Humans.
Abstract
Multiple targets and pathways may be amenable to the development of gene therapy approaches for Parkinson's disease. This article discusses some of the cellular and brain circuit pathways relevant to Parkinson's disease that would be clinically amenable to gene therapy. Approaches could be classified according to two main categories, i.e. symptomatic vs. neuroprotective/neurorestorative strategies. Examples of the different possibilities currently in development are given and feature both dopaminergic and non-dopaminergic symptomatic treatments of parkinsonian symptoms and/or L-DOPA-induced side effects, anti-apoptotic neuroprotective strategies and growth-factor delivery for neuroprotection/ neurorestoration. While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000926
- to stream PascalFrancis, to step Curation: 000A83
- to stream PascalFrancis, to step Checkpoint: 000724
- to stream Main, to step Merge: 002705
- to stream PubMed, to step Corpus: 000D26
- to stream PubMed, to step Curation: 000C86
- to stream PubMed, to step Checkpoint: 000C86
- to stream Ncbi, to step Merge: 000773
- to stream Ncbi, to step Curation: 000773
- to stream Ncbi, to step Checkpoint: 000773
- to stream Main, to step Merge: 002487
- to stream Main, to step Curation: 002495
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Grégory" last="Porras">Grégory Porras</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0178442</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0178442 INIST</idno><idno type="RBID">Pascal:08-0178442</idno><idno type="wicri:Area/PascalFrancis/Corpus">000926</idno><idno type="wicri:Area/PascalFrancis/Curation">000A83</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000724</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000724</idno><idno type="wicri:doubleKey">0014-4886:2008:Porras G:preclinical:development:of</idno><idno type="wicri:Area/Main/Merge">002705</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17904121</idno><idno type="wicri:Area/PubMed/Corpus">000D26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D26</idno><idno type="wicri:Area/PubMed/Curation">000C86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C86</idno><idno type="wicri:Area/PubMed/Checkpoint">000C86</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C86</idno><idno type="wicri:Area/Ncbi/Merge">000773</idno><idno type="wicri:Area/Ncbi/Curation">000773</idno><idno type="wicri:Area/Ncbi/Checkpoint">000773</idno><idno type="wicri:doubleKey">0014-4886:2008:Porras G:preclinical:development:of</idno><idno type="wicri:Area/Main/Merge">002487</idno><idno type="wicri:Area/Main/Curation">002495</idno><idno type="wicri:Area/Main/Exploration">002495</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease</title><author><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Grégory" last="Porras">Grégory Porras</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>CNRS UMR 5227, Universite Victor Segalen-Bordeaux 2</s1><s2>33076 Bordeaux</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Apoptosis</term><term>Asymptomatic</term><term>Basal ganglion</term><term>Clinical Trials as Topic</term><term>Dopamine</term><term>Dopamine Agents (therapeutic use)</term><term>Gene therapy</term><term>Genetic Therapy (trends)</term><term>Growth factor</term><term>Humans</term><term>Nervous system diseases</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (therapy)</term><term>Parkinson disease</term><term>Subthalamic nucleus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agents</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Genetic Therapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Humans</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Asymptomatique</term><term>Thérapie génique</term><term>Dopamine</term><term>Noyau gris central</term><term>Noyau sousthalamique</term><term>Apoptose</term><term>Facteur croissance</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Multiple targets and pathways may be amenable to the development of gene therapy approaches for Parkinson's disease. This article discusses some of the cellular and brain circuit pathways relevant to Parkinson's disease that would be clinically amenable to gene therapy. Approaches could be classified according to two main categories, i.e. symptomatic vs. neuroprotective/neurorestorative strategies. Examples of the different possibilities currently in development are given and feature both dopaminergic and non-dopaminergic symptomatic treatments of parkinsonian symptoms and/or L-DOPA-induced side effects, anti-apoptotic neuroprotective strategies and growth-factor delivery for neuroprotection/ neurorestoration. While gene therapy has been mostly used so far for enhancing the expression of the target gene, the use of dominant negative or siRNA opens new possibilities. This, combined with the key feature of gene delivery that offers access to intracellular signalling pathways, is likely to further expand the number of proposed targets to be studied.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Porras, Gregory" sort="Porras, Gregory" uniqKey="Porras G" first="Grégory" last="Porras">Grégory Porras</name></region><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002495 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002495 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:08-0178442
|texte= Preclinical development of gene therapy for Parkinson's disease : Gene therapy for parkinson's disease
}}
| This area was generated with Dilib version V0.6.29. |  |